CLINICALSTUDY AGREEMENT SMLOUVA O KLINICKÉSTUDII PROTOCOL: D5780C00007 PROTOKOL: D5780C00007 SITE: 2003636 PRACOVIŠTĚ: 2003636 POSKYTOVATELZDRAVOTNÍCHSLUŽEB: FAKULTNÍ PROVIDER: FAKULTNINEMOCNICEHRADEC KRALOVE NEMOCNICEHRADEC KRÁLOVÉ MEDIMMUNE, LLC...Clinicalstudy Agreement • June 22nd, 2018
This clinical study agreement (“Agreement”), effective as of date of publishing in contract registry in accordance with Clause 10.8 hereto (the “Effective Date”), is entered into by and among Medpace Clinical Research, LLC, with its principal office and place of business at 5375 Medpace Way, Cincinnati, Ohio 45227 ("Medpace”), represented by
CLINICALSTUDY AGREEMENTClinicalstudy Agreement • May 26th, 2021
CLINICALSTUDY AGREEMENT SMLOUVA O PROVEDENÍ KLINICKÉHO HODNOCENÍ This clinical study agreement (“Agreement”), effective as of the day of publication in the Contracts Registry (the “Effective Date”), is entered into by and amongMedpace Clinical Research, LLC, with its principal office and place of business at 5375 Medpace Way, Cincinnati, Ohio 45227 (“Medpace”), represented by; Fakultni nemocnice Hradec Králove, with its principal office at Sokolská 581, 500 05 Hradec Králové - Nový Hradec Králové, the Czech Republic (“Institution”), represented by prof. MUDr. Vladimírem Paličkou, CSc., dr.h.c., director;and with his place ofbusiness at IV. interní hematologická klinika Fakultní nemocnice Hradec Králové, Sokolská 581, 500 05 Hradec Králové – Nový Hradec Králové, Česká republika (“Investigator”).Medpace, Institution, and Investigator are sometimes collectively referred to herein each as a “Party” or collectively as the “Parties”. WHEREAS, Kartos Therapeutics, 275 Shoreline Drive, Redwood
ContractClinicalstudy Agreement • May 26th, 2023
CLINICALSTUDY AGREEMENT PROTOCOL: NS-065/ NCNP-01-302 SITE: 432 SPONSORNAME: NSPHARMA, INC. 14-APR-2023VERSION: VERSION #1 COUNTRY: CZECHREPUBLIC SMLOUVA O KLINICKÉM HODNOCENÍ PROTOKOL: NS-065/ NCNP-01-302 CENTRUM: 432 NÁZEV ZAD AVATELE: NSPHARMA, INC.14-APR-2023 VERZE: VERZEČ. 1 ZEMĚ: ČESKÁ REPUBLIKA CLINICALSTUDY AGREEMENT This clinical study agreement (“Agreement”), effective as of upon publication in the Contracts Registry (the “Effective Date”), is entered into by and among Medpace Clinical Research, LLC, with its principal office and place of business at 5375 Medpace Way, Cincinnati, Ohio 45227 ("Medpace”), represented by , Director, Clinical Operations;andFakultní nemocnicí Hradec Králové with its principal office and place of business at Sokolská 581, 500 05 Hradec Králové – Nový Hradec Králové, Czech Republic ("Institution”), represented by its director, MUDr. Aleš Herman, Ph.D;andwith his/her principal office and place of business at Fakultní nemocnice Hradec Králové, Neurolo
